8-K: Artiva Biotherapeutics Announces Executive Changes
Executive Changes
Artiva Biotherapeutics has appointed Diego Miralles as President and Head of R&D, while CFO Thad Huston departs.
Summary
- Artiva Biotherapeutics, Inc. announced several executive changes effective May 18, 2026.
- Diego Miralles, M.D., resigned from the Board of Directors to become President and Head of Research and Development.
- Thad Huston will depart as Chief Financial Officer on May 22, 2026, receiving a separation package including three months' salary and up to nine months of COBRA.
- Fred Aslan, M.D., remains CEO and a Board member, and has also been appointed as the principal financial and accounting officer.
- Dr. Miralles' new role includes an annual base salary of $600,000, eligibility for a 45% target bonus, and inducement awards of stock options and RSUs.
- The Board size has been reduced from eight to seven members following Dr. Miralles' resignation from the Board.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it involves standard executive transitions and appointments without immediate positive or negative financial implications disclosed in this filing.
Positives
- Appointment of Diego Miralles to President and Head of Research and Development, leveraging his expertise.
- Fred Aslan retaining CEO role and taking on principal financial and accounting officer duties, ensuring continuity.
- Dr. Miralles' compensation package includes significant equity awards (232,500 stock options, 77,500 RSUs) intended to incentivize performance.
- Clear separation terms for CFO Thad Huston, providing a defined exit with severance.
Negatives
- Departure of Chief Financial Officer Thad Huston, necessitating a search for a replacement.
- Reduction in Board size from eight to seven members, potentially impacting governance dynamics.
Risks
- The company needs to find a new CFO, which could lead to a period of instability or impact financial operations.
- The transition of key executive roles could create temporary operational challenges.
- The effectiveness of Dr. Miralles in his new dual role as President and Head of R&D remains to be seen.
Future Outlook
The filing does not contain specific forward-looking financial guidance. However, the appointment of Dr. Miralles to lead R&D and the continued role of Dr. Aslan as CEO suggest a focus on operational continuity and strategic development.
Management Comments
- Diego Miralles, M.D. resigned as a member of the Board of Directors in connection with his appointment as President and Head of Research and Development.
- Thad Huston and the Company agreed to Mr. Huston's separation from his position as Chief Financial Officer.
- Fred Aslan, M.D. resigned as President in connection with Dr. Miralles' appointment as President and Head of Research and Development, and remains Chief Executive Officer and a member of the Board.
- Dr. Miralles will receive an annual base salary of $600,000 and will be eligible for a discretionary annual cash bonus with a target of 45% of his base salary.
Industry Context
StockSavvy.ai notes that executive reshuffling, particularly involving R&D leadership and CFO transitions, is common in the biotechnology sector as companies advance drug candidates or navigate financial strategies. The focus on R&D leadership by appointing Dr. Miralles suggests a strategic emphasis on pipeline development.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Diego Miralles, M.D. | May 18, 2026 | Appointment as President and Head of Research and Development. | |
| Chief Financial Officer | Thad Huston | May 22, 2026 | Separation agreement with the Company. | |
| President | Fred Aslan, M.D. | May 18, 2026 | Appointment of Dr. Miralles as President and Head of Research and Development. | |
| Principal Financial Officer and Principal Accounting Officer | Fred Aslan, M.D. | May 18, 2026 | Appointment by the Company. | |
| President and Head of Research and Development | Diego Miralles, M.D. | May 18, 2026 | Appointment by the Company. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Size Reduction | The size of the Board of Directors was reduced from eight members to seven members. | May 18, 2026 | May slightly alter board dynamics and committee composition, but is a common adjustment following executive role changes. |
Stakeholder Impact
- Shareholders: May experience short-term uncertainty due to CFO departure, but strategic R&D leadership appointment could be viewed positively.
- Employees: Potential impact on team morale and workload during the CFO search; clarity on Dr. Miralles' new role provides direction for R&D teams.
- Creditors: No immediate impact indicated, as financial oversight is transitioning.
Next Steps
- Artiva Biotherapeutics will conduct a search for a replacement Chief Financial Officer.
- Dr. Miralles will commence his new role as President and Head of Research and Development.
- Dr. Miralles' stock options and RSUs will begin vesting starting May 15, 2027.
Key Dates
| Date | Description |
|---|---|
| April 30, 2026 | Filing of Amendment No.1 to Annual Report on Form 10-K/A for the fiscal year ended December 31, 2025, containing biographies of Drs. Aslan and Miralles. |
| March 10, 2026 | Filing of Annual Report on Form 10-K for the fiscal year ended December 31, 2025, containing forms of Option and RSU agreements. |
| June 28, 2024 | Filing of Registration Statement on Form S-1, containing standard form of Indemnity Agreement for officers. |
| May 18, 2026 | Effective date of Dr. Miralles' resignation from the Board and appointment as President and Head of R&D; effective date of Dr. Aslan's appointment as principal financial and accounting officer; date of Separation Agreement with Thad Huston. |
| May 19, 2026 | Date of the report filing. |
| May 22, 2026 | Separation Date for Chief Financial Officer Thad Huston. |
| May 15, 2027 | First vesting date for Dr. Miralles' stock options and RSUs. |
Recommendation
holdThis filing details executive changes, including a CFO departure and the appointment of a new R&D head. While these are significant internal shifts, they do not provide new financial performance data or strategic breakthroughs that would warrant a strong buy or sell recommendation at this juncture. The company is in a transition phase for key leadership roles.
Keywords
Artiva Biotherapeutics, Executive Changes, President, Chief Financial Officer, Research and Development, Board of Directors, Form 8-K, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.